RxSight, Inc. Presents Second Quarter 2025 Revenue, Reiterates Full-Year Guidance

Published on August 8, 2025
ALISO VIEJO, Calif.—RxSight, Inc. (NASDAQ: RXST), an ophthalmic medical device company providing customized vision to patients following cataract surgery, yesterday shared results for its second quarter ending June 30, 2025, with total revenue reported at $33.6 million, down 4 percent compared with $34.9 million in the second quarter of 2024. The company said these results reflect an increase in procedure volume and decrease in light delivery device (LDD) sales, compared with the same period last year.
Continue reading on website
Other news

Parental lag time is primary reason for delayed diagnosis and treatment of retinoblastoma

August 7, 2025
Ocular salvage and preservation of vision are essentially dependent on early diagnosis, and several studies have been conducted to identify the factors leading to delayed diagnosis at presentation.

The future of optometry: Dr Rachelle Lin taking the low vision world by storm

August 8, 2025
Rachelle Lin, OD, MS, FAAO, has refined her passions for academia, teaching, low vision practice, and advocacy work to build out a well-rounded career.